Inhibition of cytochrome P4502C9 activity in vitro by 5-hydroxytryptamine and adrenaline

被引:15
|
作者
Gervasini, G
Martínez, C
Agúndez, JAG
García-Gamito, FJ
Benítez, J
机构
[1] Univ Extremadura, Fac Med, Dept Farmacol, E-06071 Badajoz, Spain
[2] INSALUD Hosp Merida, Serv Gen Surg, Badajoz, Spain
来源
PHARMACOGENETICS | 2001年 / 11卷 / 01期
关键词
diclofenac; CYP2C9; microsomes;
D O I
10.1097/00008571-200102000-00004
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
In the present study, the occurrence of a modulatory effect of 14 neurotransmitters, precursors and metabolites on the cytochrome P450 2C9 (CYP2C9) enzyme activity, as determined by diclofenac 4-hydroxylation, was studied in human liver microsomes. Two indoleamines, 5-hydroxytryptamine (5-HT) and adrenaline, showed a non-competitive-type inhibitory effect of approximately 90% of the diclofenac 4-hydroxylase activity, with K-i values of 63.5 (0.7 and 156 (89.3 muM, respectively. The rest of substances analysed were weak inhibitors or had no inhibitory effect, CYP2C subfamily is present in human brain, although CYP2C9 isozyme has not yet been identified in this tissue, and CYP2C9 is involved in the metabolism of psychoactive drugs. Therefore, the fact that endogenous compounds could modulate the CYP2C9 activity, suggests that an hypothetical local activity of brain CYP2C9 might be susceptible to regulatory mechanisms. The possible clinical implications of this modulation are discussed. Pharmacogenetics 11:29-37 (C) Lippincott Williams & Wilkins.
引用
收藏
页码:29 / 37
页数:9
相关论文
共 50 条
  • [21] Implications of cytochrome P4502C9 polymorphism on Warfarin metabolism and dosing
    Redman, AR
    PHARMACOTHERAPY, 2001, 21 (02): : 235 - 242
  • [22] Oxidation of celecoxib by polymorphic cytochrome P4502C9 and alcohol dehydrogenase
    Sandberg, M
    Yasar, Ü
    Strömberg, P
    Höög, JO
    Eliasson, E
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (04) : 423 - 429
  • [23] Exploring the routes out of the active site of cytochrome P4502C9
    Cojocaru, Vlad
    BIOPHYSICAL JOURNAL, 2007, : 376A - 376A
  • [24] Crystal structure of human cytochrome P4502C9 with bound warfarin
    Williams, PA
    Cosme, J
    Ward, A
    Angova, HC
    Vinkovic, DM
    Jhoti, H
    NATURE, 2003, 424 (6947) : 464 - 468
  • [25] Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite
    Bajpai, M
    Roskos, LK
    Shen, DD
    Levy, RH
    DRUG METABOLISM AND DISPOSITION, 1996, 24 (12) : 1401 - 1403
  • [26] Cytochrome P4502C9 mediated metabolism in people with and without cancer
    Shord, S. S.
    Cavallari, L. H.
    Viana, M. A. G.
    Momary, K.
    Neceskas, J.
    Molokie, R. E.
    Deyo, K.
    Patel, S. R.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2008, 46 (07) : 365 - 374
  • [27] Effects of cytochrome P4502C9 polymorphisms on phenprocoumon anticoagulation status
    Schalekamp, T
    Oosterhof, M
    van Meegen, E
    van der Meer, FJM
    Conemans, J
    Hermans, M
    Meijerman, I
    de Boer, A
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (05) : 409 - 417
  • [28] Frequency of cytochrome P4502C9 mutant alleles in a Korean population
    Yoon, YR
    Shon, JH
    Kim, MK
    Lim, YC
    Lee, HR
    Park, JY
    Cha, IJ
    Shin, JG
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 51 (03) : 277 - 280
  • [29] Development of a combined protein and pharmacophore model for cytochrome P4502C9
    de Groot, MJ
    Alex, AA
    Jones, BC
    JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (10) : 1983 - 1993
  • [30] Crystallization of human P4502C9
    Wester, MR
    Stout, CD
    Schoch, G
    Yano, JK
    Johnson, EF
    FASEB JOURNAL, 2003, 17 (04): : A609 - A609